Myeloma Multiple
49
21
24
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.2%
4 terminated out of 49 trials
71.4%
-15.2% vs benchmark
6%
3 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (49)
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
The Norwegian Immunotherapy in Multiple Myeloma Study
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study
Feasibility of a Multi-omics Platform for Hematological Malignancies
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment